Single-centre experience with next-generation devices for transapical aortic valve implantation†

    loading  Checking for direct PDF access through Ovid

Abstract

OBJECTIVES

Transcatheter aortic valve implantation (TAVI) has become an established procedure in patients with aortic stenosis and high surgical risk. Experience with first-generation transcatheter heart valves (THVs) is broad but limitations, e.g. paravalvular regurgitation, have been demonstrated. Much hope rests on the recently Conformité Européenne mark approved next-generation devices to improve results in these patients. However, apart from the initial approval studies, clinical data with these new devices are still scarce. We aimed to assess short-term outcomes of 200 consecutive patients who underwent transapical TAVI with next-generation THV at our institution.

METHODS

Transapical TAVI was performed in 200 consecutive patients 80.5 ± 6.7 years old (38.5% female) at high surgical risk (log EuroSCORE 20.2 ± 16.5%). Devices implanted were the Engager (Medtronic, Inc., Minneapolis, MN, USA; n = 50), JenaValve (JenaValve Technology, Munich, Germany; n = 88) and Symetis Acurate (Symetis SA, Ecublens, Switzerland; n = 62) THV that were selected by the heart team on an individual basis. Data at baseline, during the procedure and follow-up were analysed according to standardized Valve Academic Research Consortium end points. Median follow-up was 219 days.

RESULTS

Implantation was successful in 96.5% of cases. Valve function improved significantly with an increase in effective orifice area from 0.8 ± 0.4 to 1.8 ± 0.3 cm2 and a reduction in mean transvalvalvular gradients from 34.0 ± 17.0 to 11.2 ± 5.4 mmHg. Paravalvular regurgitation was none or trace in 70.3% of patients, Grade 1 in 26.1%, and Grade 2 in 3.5%. No patients developed aortic regurgitation > Grade 2. Major access site complications occurred in 6.5%, major stroke in 1.5% and stage-3 kidney injury in 2.5% of patients. A permanent pacemaker was implanted in 20.5% of patients overall and in 8.0% for a complete heart block. At 30-day follow-up 72.8% of patients were in New York Heart Association class I or II (10.5% at baseline). Overall survival was 91.5% at 30 days and 73.9% at 1 year.

CONCLUSIONS

In a real-world clinical setting, next-generation transapical THV yielded positive haemodynamic results. The incidence of relevant paravalvular regurgitation was scarce in this group and clinical outcomes were encouraging during short-term follow-up. Long-term follow-up is required to investigate the durability of these new devices.

Related Topics

    loading  Loading Related Articles